Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on KYOWA HAKKO KIRIN CO LTD
11/10 KYOWA HAKKO KIRIN : Data from Kyowa Hakko Kirin Co. Ltd. Advance Knowledge in Di..
10/20 KYOWA HAKKO KIRIN : New Hypercalcemia Study Findings Have Been Reported by Inves..
09/29 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
09/28 KYOWA HAKKO KIRIN : Launch of LUMICEF for Psoriasis Treatment, in Japan
09/28 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
09/27 KYOWA HAKKO KIRIN : Launch of LUMICEF® for Psoriasis Treatment, in Japan
09/21 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
09/21 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
09/20 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
09/20 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
09/19 Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the ..
09/15 KYOWA HAKKO KIRIN : Reports Summarize Colon Cancer Study Results from Kyowa Hakk..
09/01 L-Tyrosine Market 2016 - Ajinomoto, Kyowa Hakko Kogyo, Douglas Laboratories, ..
08/09 Kyowa Hakko Kirin Announced Kyowa Medex Acquired approval for Insurance Cover..
08/08 KYOWA HAKKO KIRIN : Announced Kyowa Medex Acquired approval for Insurance Covera..
07/21 KYOWA HAKKO KIRIN : Patent Issued for Pharmaceutical Composition Comprising Anti..
07/07 KYOWA HAKKO KIRIN : Researchers at Kyowa Hakko Kirin Co. Ltd. Release New Data o..
07/04 KYOWA HAKKO KIRIN : LUMICEF® approved in Japan(112KB)
06/29 Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric P..
06/29 KYOWA HAKKO KIRIN : US Food and Drug Administration Granted Breakthrough Therapy..
06/28 KYOWA HAKKO KIRIN : US Food and Drug Administration Granted Breakthrough Therapy..
06/28 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
06/23 KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co. Ltd. Describe New Finding..
06/09 KYOWA HAKKO KIRIN : Researchers from Kyowa Hakko Kirin Co. Ltd. Provide Details ..
06/07 Medgenics Enters into Agreement with Kyowa Hakko Kirin
06/06 KYOWA HAKKO KIRIN : Announces Preliminary Results from Pivotal Phase 2 Study of ..
06/06 GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson %..
06/06 KYOWA HAKKO KIRIN : Announces Preliminary Results from Pivotal Phase 2 Study of ..
06/02 KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co. Ltd. Add New Findings in ..
05/24 KYOWA HAKKO KIRIN : Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal ..
05/23 KYOWA HAKKO KIRIN : Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal ..
05/17 Positive benralizumab results in severe asthma
04/19 KYOWA HAKKO KIRIN : Borders-based pharma firm in Japanese-led rebrand
04/19 KYOWA HAKKO KIRIN : ProStrakan rebrands as Kyowa Kirin International PLC
04/19 KYOWA HAKKO KIRIN : Medicine firm aims to unify its image with a rebrand
04/18 KYOWA HAKKO KIRIN : ProStrakan rebrands as Kyowa Kirin
04/04 KYOWA HAKKO KIRIN : BioWa Announces Office Relocation to Princeton, NJ and appoi..
04/01 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders
04/01 KYOWA HAKKO KIRIN : BioWa Announces Office Relocation to Princeton, NJ and appoi..
03/31 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders(44KB)
03/24 KYOWA HAKKO KIRIN : Notice regarding allotment of stock acquisition rights (stoc..
03/15 AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business ..
03/02 ProStrakan acquires rights for drug easing side effect of pain pills
03/02 KYOWA HAKKO KIRIN : Initiation of Operations for Drug Product Manufacturing Faci..
03/01 AstraZeneca enters into agreement with ProStrakan for rights to Moventig in E..
03/01 KYOWA HAKKO KIRIN : AstraZeneca sells drug for $70 million as divestment drive c..
02/29 KYOWA HAKKO KIRIN : Entries Now Publicly Available from the 'Commitment to Life'..
02/26 KYOWA HAKKO KIRIN : Change of Representative Directors at Kyowa Medex(31KB)
02/19 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for the purpose of..
02/11 KYOWA HAKKO KIRIN : Patent Issued for Therapeutic Agent for Mood Disorders (USPT..
02/04 KYOWA HAKKO KIRIN : Data on Immunoglobulins Reported by Researchers at Kyowa Hak..
02/04 KYOWA HAKKO KIRIN : Study Results from Kyowa Hakko Kirin Co. Ltd. Broaden Unders..
02/01 KYOWA HAKKO KIRIN : Change in the Company Name of Western Pharmaceutical Subsidi..
01/29 KYOWA HAKKO KIRIN : Announces FY2016-2020 Mid-term Business Plan(123KB)
01/29 KYOWA HAKKO KIRIN : Consolidated Financial Summary Fiscal 2015(221KB)
01/29 KYOWA HAKKO KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2015(1..
01/29 KYOWA HAKKO KIRIN : Results Presentation Fiscal 2015(1,924KB)
01/29 KYOWA HAKKO KIRIN : Change in the Company Name of Western Pharmaceutical Subsidi..
01/26 Kyowa Hakko Kirin Entered an Agreement with Sandoz for Exclusive Marketing Ri..
01/14 KYOWA HAKKO KIRIN : Reports from Kyowa Hakko Kirin Co. Ltd. Provide New Insights..
01/11 KYOWA HAKKO KIRIN : BioWa opens POTELLIGENT® Technology license to customers for..
01/07 KYOWA HAKKO KIRIN : Investigators from Kyowa Hakko Kirin Co. Ltd. Release New Da..
2015 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for final dividend
2015 KYOWA HAKKO KIRIN : Launch of the Web Comic "The Story of Basic Immunology"
2015 Kyowa Medex Launched 'Liaison 25 -hydroxyvitamin D Total' in Japan
2015 KYOWA HAKKO KIRIN : Medex Launched "Liaison 25 -hydroxyvitamin D Total" in Japan
2015 Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 ..
2015 KYOWA HAKKO KIRIN : Announces Commencement of Phase 3 Clinical Study of KHK7580 ..
2015 KYOWA HAKKO KIRIN : Consolidated Financial Summary Fiscal 2015 Third Quarter(110..
2015 KYOWA HAKKO KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2015 T..
2015 KYOWA HAKKO KIRIN : Notice Concerning Change of the Number of Shares to Constitu..
2015 Valeant picks up AstraZeneca psoriasis drug after Amgen exit
2015 KYOWA HAKKO KIRIN : Submits Application for Approval in Japan for Brodalumab (KH..
2015 KYOWA HAKKO KIRIN : initiated a Pivotal Phase 3 Trial of Benralizumab (KHK4563) ..
2015 KYOWA HAKKO KIRIN : Launch of Reconfigured Kyowa Hakko Kirin Global Website
1  2  3Next
Advertisement
Financials ( JPY)
Sales 2016 346 714 M
EBIT 2016 -
Net income 2016 19 150 M
Finance 2016 26 962 M
Yield 2016 1,55%
P/E ratio 2016 42,83
P/E ratio 2017 40,06
EV / Sales 2016 2,61x
EV / Sales 2017 2,52x
Capitalization 931 021 M
More Financials
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Full-screen chart
Technical analysis trends KYOWA HAKKO KIRIN...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 2 077  JPY
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Koichiro Nishikawa Independent Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO L..-15.22%8 200
ABBVIE INC0.32%96 580
MERCK KGAA3.13%12 750
JAZZ PHARMACEUTICALS P..-26.27%6 128
MALLINCKRODT PLC-28.17%5 675
ZHANGZHOU PIENTZEHUANG..3.84%4 112
More Results